253 related articles for article (PubMed ID: 16641449)
1. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
Joos B; Trkola A; Kuster H; Aceto L; Fischer M; Stiegler G; Armbruster C; Vcelar B; Katinger H; Günthard HF
Antimicrob Agents Chemother; 2006 May; 50(5):1773-9. PubMed ID: 16641449
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.
Nakowitsch S; Quendler H; Fekete H; Kunert R; Katinger H; Stiegler G
AIDS; 2005 Nov; 19(17):1957-66. PubMed ID: 16260901
[TBL] [Abstract][Full Text] [Related]
3. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
[TBL] [Abstract][Full Text] [Related]
4. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
Alam SM; McAdams M; Boren D; Rak M; Scearce RM; Gao F; Camacho ZT; Gewirth D; Kelsoe G; Chen P; Haynes BF
J Immunol; 2007 Apr; 178(7):4424-35. PubMed ID: 17372000
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
Binley JM; Wrin T; Korber B; Zwick MB; Wang M; Chappey C; Stiegler G; Kunert R; Zolla-Pazner S; Katinger H; Petropoulos CJ; Burton DR
J Virol; 2004 Dec; 78(23):13232-52. PubMed ID: 15542675
[TBL] [Abstract][Full Text] [Related]
6. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12.
Armbruster C; Stiegler GM; Vcelar BA; Jäger W; Köller U; Jilch R; Ammann CG; Pruenster M; Stoiber H; Katinger HW
J Antimicrob Chemother; 2004 Nov; 54(5):915-20. PubMed ID: 15456731
[TBL] [Abstract][Full Text] [Related]
7. MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide.
Morris GC; Wiggins RC; Woodhall SC; Bland JM; Taylor CR; Jespers V; Vcelar BA; Lacey CJ
PLoS One; 2014; 9(12):e116153. PubMed ID: 25546420
[TBL] [Abstract][Full Text] [Related]
8. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
Stiegler G; Kunert R; Purtscher M; Wolbank S; Voglauer R; Steindl F; Katinger H
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1757-65. PubMed ID: 11788027
[TBL] [Abstract][Full Text] [Related]
9. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
[TBL] [Abstract][Full Text] [Related]
10. Antigenic properties of the HIV envelope on virions in solution.
Ray K; Mengistu M; Yu L; Lewis GK; Lakowicz JR; DeVico AL
J Virol; 2014 Feb; 88(3):1795-808. PubMed ID: 24284318
[TBL] [Abstract][Full Text] [Related]
11. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
[TBL] [Abstract][Full Text] [Related]
12. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.
Shen X; Parks RJ; Montefiori DC; Kirchherr JL; Keele BF; Decker JM; Blattner WA; Gao F; Weinhold KJ; Hicks CB; Greenberg ML; Hahn BH; Shaw GM; Haynes BF; Tomaras GD
J Virol; 2009 Apr; 83(8):3617-25. PubMed ID: 19193787
[TBL] [Abstract][Full Text] [Related]
13. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.
Alam SM; Scearce RM; Parks RJ; Plonk K; Plonk SG; Sutherland LL; Gorny MK; Zolla-Pazner S; Vanleeuwen S; Moody MA; Xia SM; Montefiori DC; Tomaras GD; Weinhold KJ; Karim SA; Hicks CB; Liao HX; Robinson J; Shaw GM; Haynes BF
J Virol; 2008 Jan; 82(1):115-25. PubMed ID: 17942537
[TBL] [Abstract][Full Text] [Related]
15. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
[TBL] [Abstract][Full Text] [Related]
16. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.
Hessell AJ; Rakasz EG; Tehrani DM; Huber M; Weisgrau KL; Landucci G; Forthal DN; Koff WC; Poignard P; Watkins DI; Burton DR
J Virol; 2010 Feb; 84(3):1302-13. PubMed ID: 19906907
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
[TBL] [Abstract][Full Text] [Related]
18. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
Chen Y; Zhang J; Hwang KK; Bouton-Verville H; Xia SM; Newman A; Ouyang YB; Haynes BF; Verkoczy L
J Immunol; 2013 Aug; 191(3):1260-75. PubMed ID: 23825311
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.
Armbruster C; Stiegler GM; Vcelar BA; Jäger W; Michael NL; Vetter N; Katinger HW
AIDS; 2002 Jan; 16(2):227-33. PubMed ID: 11807307
[TBL] [Abstract][Full Text] [Related]
20. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
Mehandru S; Wrin T; Galovich J; Stiegler G; Vcelar B; Hurley A; Hogan C; Vasan S; Katinger H; Petropoulos CJ; Markowitz M
J Virol; 2004 Dec; 78(24):14039-42. PubMed ID: 15564511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
